Status:
COMPLETED
Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Psoriatic Arthritis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of the study was to compare the efficacy of 2 different Etanercept regimens for the treatment of skin and joint manifestations of psoriatic arthritis.
Eligibility Criteria
Inclusion
- 18 years of age or older at time of consent
- Active Psoriatic Arthritis
- Clinically stable, plaque psoriasis involving more than 10% of the body surface area
Exclusion
Key Trial Info
Start Date :
December 27 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 29 2008
Estimated Enrollment :
752 Patients enrolled
Trial Details
Trial ID
NCT00245960
Start Date
December 27 2005
End Date
March 29 2008
Last Update
January 31 2022
Active Locations (120)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital A Posadas
Palomar, Buenos Aires, Argentina, 1684
2
Hospital General de Agudos
Buenos Aires, Argentina, C1001AFA
3
Hospital Italiano de Buenos Aires
Buenos Aires, Argentina, C1001AFA
4
CEMIC
Buenos Aires, Argentina, C1014ADB